It’s new-drug-journal-club time! In a world bereft of (many) therapeutic options for sickle cell disease, we want to introduce you to the newest kid on the block: voxelotor. But first, we have to determine if this is a relationship worth starting, and we’ll do that by looking at the data.
Read MoreFor most pharmacists, encounters with sickle cell disease are few and far between. However, if you work in a city (particularly if it's an international hub such as DC or New York), you will encounter sickle cell somewhat regularly.
Read More